Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Next Deadline
163 days remaining
NOA E-Mailed - SOU Required
Due Date
May 30, 2026
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 26, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 26, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Nov 23, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Nov 24, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 17, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 16, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 16, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 16, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 11, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 12, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Dec 9, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 23, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 22, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 22, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 22, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 23, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 21, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 21, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 21, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 30, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 4, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 4, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 15, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 1, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 1, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 1, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 1, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 1, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Feb 7, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 6, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 6, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 31, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 31, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 31, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 4, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 3, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 3, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 4, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 4, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 4, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 31, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 18, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 25, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; Biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; Biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; Lipid nanoparticles for scientific, laboratory or medical research use
Class 005
Vaccine adjuvants; Drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals
Class 042
Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
Class 044
Medical services; medical information; providing a website featuring medical information
Classification
International Classes
001
005
042
044